Nataliya P. Buxbaum, M.D.

Nataliya P. Buxbaum, M.D.
Assistant Clinical Investigator

Dr. Buxbaum is a bone marrow transplant (BMT) physician-scientist studying immune-mediated barriers to successful BMT.  Dr. Buxbaum’s laboratory and clinical investigations are centered on chronic graft-versus-host disease (cGVHD), which occurs when the immune cells of the donor recognize the organs of the recipient as foreign with resultant damage to these tissues.  An increasing number of BMT patients are affected by cGVHD, hence there is an increased need for new and effective treatments for this disease.  Dr. Buxbaum’s  research efforts are focused on understanding the biology of cGVHD through the use of pre-clinical models and evaluating pediatric patients on the Natural History of cGVHD study at the NCI.

Areas of Expertise
1) chronic graft-versus-host disease (cGVHD), 2) bone marrow transplantation (BMT), 3) pediatric cancer, 4) T cell subsets, 5) in vivo cell kinetics, 6) stable water isotopes

Contact Info

Nataliya P. Buxbaum, M.D.
Center for Cancer Research
National Cancer Institute
Building 10, Room 3-3288
Bethesda, MD 20892-1203
Ph: 240-760-6157
Fax: 240-541-4566
nbuxbaum@mail.nih.gov

Dr. Buxbaum is elucidating the biology of immunologic events that underlie chronic graft-versus-host disease (cGVHD).   T cells are central to cGVHD pathophysiology. Through the use of stable water isotope labeling Dr. Buxbaum gained insight into differential in vivo behavior of key T cell subsets in the pre-clinical cGVHD model.  Dr. Buxbaum is now exploiting these biological differences to develop novel clinical imaging methods for cGVHD.  Furthermore, Dr. Buxbaum is working on identifying new therapeutic targets and treatments for cGVHD in the pre-clinical model that will be translated into clinical studies for patients affected by cGVHD.

Scientific Focus Areas:
Cell Biology, Chemical Biology, Clinical Research, Immunology, Stem Cell Biology

Selected Publications

  1. Buxbaum NP, Farthing DE, Maglakelidze N, Lizak M, Merkle H, Carpenter AC, Oliver BU, Kapoor V, Castro E, Swan GA, Dos Santos LM, Bouladou, NJ, Bare CV, Flomerfelt FA, Eckhaus MA, Telford WG, Belkaid Y, Bosselut RJ, Gress, RE
    JCI Insight. 2: 2017. [ Journal Article ]
  2. Comparing DNA enrichment of proliferating cells following administration of different stable isotopes of heavy water.
    Farthing DE, Buxbaum NP, Lucas, PJ, Maglakelidze N, Oliver BU, Wang J, Hu K, Castro E, Bare CV, Gress, RE
    Scientific Reports. 7: 4043, 2017. [ Journal Article ]
  3. Chronic GVHD in Children.
    Baird K and Buxbaum NP.
    In: Graft Versus Host Disease: Living With The After Effects of Bone Marrow/Stem Cell Transplant. nbmtLINK 49-56, 2015. [ Book Chapter ]
  4. Farthing DF, Buxbaum NP, Bare CV, Treadwell SM, Kapoor V, Williams KW, and Gress RE.
    Anal Chem. 85(9): 4613-20, 2013. [ Journal Article ]
  5. Jegalian AG, Buxbaum NP, Fancchetti F, Raffeld M, Pittaluga S, Wayne A, and Jaffe ES.
    Haematologica. 95(11): 1873-9, 2010. [ Journal Article ]

Dr. Buxbaum first came to the NIH as a Howard Hughes Medical Institute (HHMI) research scholar in 2002.  She graduated from Rutgers Robert Wood Johnson Medical School in New Brunswick, NJ in 2005 and completed her residency in Pediatrics at Columbia Presbyterian, Children’s Hospital of New York in 2008.  She then trained in Pediatric Hematology-Oncology through the Johns Hopkins and National Cancer Institute (NCI) combined fellowship. Dr. Buxbaum is board certified in Pediatrics (2009) and Pediatric Hematology Oncology (2013) and currently serves as an Assistant Clinical Investigator in the Experimental Transplantation and Immunology Branch, NCI.

Name Position
Julian Assmann Ph.D. Postdoctoral Fellow (Visiting)
Donald E. Farthing Ph.D. Biochemist (Contr.)
Kathrynne Warrick B.S. Postbaccalaureate Fellow (IRTA/CRTA)